| Abstract: | Anti-angiogenic vascular endothelial growth factor A (VEGF)165b and pro-angiogenic VEGF165 are generated from the same transcript, and their relative amounts are dependent on alternative splicing. The role of VEGF165b has not been investigated in as much detail as VEGF165, although it appears to be highly expressed in non-angiogenic tissues and, in contrast with VEGF165, is downregulated in tumors and other pathologies associated with abnormal neovascularization such as diabetic retinopathy or Denys Drash syndrome. VEGF165b inhibits VEGFR2 signaling by inducing differential phosphorylation, and it can be used to block angiogenesis in in vivo models of tumorigenesis and angiogenesis-related eye disease. Recent reports have identified three serine/arginine-rich proteins, SRSF1, SRSF2 and SRSF6, and studied their role in regulating terminal splice-site selection. Since the balance of VEGF isoforms is lost in cancer and angiogenesis-related conditions, control of VEGF splicing could also be used as a basis for therapy in these diseases. |
